ELI LILLY & Co (LLY) — SEC Filings

Latest SEC filings for ELI LILLY & Co (LLY), explained in plain English.

Sentiment Overview: 2 bullish, 28 neutral

Recent Filings (30)

• 8-K Filing — 8-K · 2025-11-21T00:00:00.000Z [neutral]
• Eli Lilly's Q3 Revenue Soars 54%, Net Income Jumps 475% — 10-Q · 2025-10-30T00:00:00.000Z [bullish] Risk: medium
  Eli Lilly and Company (LLY) reported a robust financial performance for the quarter ended September 30, 2025, with revenue surging to $17,600.8 million, a signi
• Eli Lilly Files 8-K on Debt Instruments — 8-K · 2025-08-20T00:00:00.000Z [neutral] Risk: low
  Eli Lilly and Company (LLY) filed an 8-K on August 20, 2025, reporting "Other Events" and "Financial Statements and Exhibits" as of August 18, 2025. The filing
• Eli Lilly's Q2 Soars on New Drug Sales, R&D Investment Continues — 10-Q · 2025-08-07T00:00:00.000Z [bullish] Risk: low
  Eli Lilly & Co. reported robust financial performance for the second quarter ended June 30, 2025, driven by strong sales of key pharmaceutical products. Revenue
• Eli Lilly Files 8-K on Security Holder Votes and Debt — 8-K · 2025-05-08T00:00:00.000Z [neutral] Risk: low
  Eli Lilly & Co. filed an 8-K on May 8, 2025, to report the submission of matters to a vote of security holders. The filing details various debt instruments, inc
• Eli Lilly Files Q1 2025 10-Q, Details Debt Maturities — 10-Q · 2025-05-01T00:00:00.000Z [neutral] Risk: low
  Eli Lilly and Company (LLY) filed its 10-Q for the period ending March 31, 2025. The filing details various financial instruments, including several series of n
• Eli Lilly Executive Compensation Details Revealed — DEF 14A · 2025-03-21T00:00:00.000Z [neutral] Risk: low
  Eli Lilly and Company (LLY) filed its DEF 14A on March 21, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing inclu
• Eli Lilly Files 2024 10-K, Details Financials — 10-K · 2025-02-19T00:00:00.000Z [neutral] Risk: low
  Eli Lilly and Company (LLY) filed its 2024 10-K on February 19, 2025, reporting on its fiscal year ending December 31, 2024. The company, a major player in phar
• Eli Lilly Files 8-K Detailing Debt Offerings — 8-K · 2025-02-12T00:00:00.000Z [neutral] Risk: low
  Eli Lilly and Company (LLY) filed an 8-K on February 12, 2025, reporting other events and financial statements. The filing details various debt issuances, inclu
• Eli Lilly Files 8-K on Financials and Debt — 8-K · 2025-02-06T00:00:00.000Z [neutral] Risk: low
  Eli Lilly and Company filed an 8-K on February 6, 2025, reporting on its results of operations and financial condition. The filing includes financial statements
• Eli Lilly Files 8-K on Financials — 8-K · 2025-01-14T00:00:00.000Z [neutral] Risk: low
  Eli Lilly and Company filed an 8-K on January 14, 2025, to report on its results of operations and financial condition. The filing includes various financial st
• Eli Lilly Elects New Directors, Adjusts Officer Compensation — 8-K · 2024-11-19T00:00:00.000Z [neutral] Risk: low
  On November 19, 2024, Eli Lilly and Company (LLY) filed an 8-K detailing the election of new directors and changes in executive compensation. Specifically, the
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• Eli Lilly & Co. Files Q3 2024 10-Q Report — 10-Q · 2024-10-30T00:00:00.000Z [neutral] Risk: medium
  Eli Lilly and Company (LLY) filed its 10-Q for the period ending September 30, 2024. The company reported its financial performance and provided updates on its
• SC 13G/A Filing — SC 13G/A · 2024-10-23T00:00:00.000Z [neutral]
• Eli Lilly Files 8-K: Director Changes and Compensation Details — 8-K · 2024-09-09T00:00:00.000Z [neutral] Risk: low
  Eli Lilly and Company (LLY) filed an 8-K on September 9, 2024, reporting on the departure of director Michael J. Smith and the election of new directors, includ
• Eli Lilly Files 8-K: Director Changes and Officer Compensation — 8-K · 2024-08-16T00:00:00.000Z [neutral] Risk: low
  Eli Lilly and Company (LLY) filed an 8-K on August 16, 2024, reporting on the departure of director Michael J. Smith and the election of new directors, includin
• Eli Lilly Files 8-K on Debt Issuances — 8-K · 2024-08-14T00:00:00.000Z [neutral] Risk: low
  Eli Lilly and Company (LLY) filed an 8-K on August 14, 2024, reporting on other events and financial statements. The filing details various debt issuances, incl
• Eli Lilly Files Q2 2024 10-Q, Details Debt — 10-Q · 2024-08-08T00:00:00.000Z [neutral] Risk: low
  Eli Lilly and Company (LLY) filed its 10-Q for the period ending June 30, 2024. The filing details the company's financial performance and position, including v
• Eli Lilly Announces Executive Compensation Changes — 8-K · 2024-07-10T00:00:00.000Z [neutral] Risk: medium
  Eli Lilly & Co. announced on July 5, 2024, changes in its executive compensation arrangements. The filing details the election of new officers and adjustments t
• Eli Lilly Announces Board Changes and Officer Compensation Details — 8-K · 2024-06-05T00:00:00.000Z [neutral] Risk: low
  Eli Lilly and Company (LLY) filed an 8-K on June 5, 2024, reporting on the departure of director Michael L. Smith and the election of new directors, including A
• Eli Lilly Files 8-K on Shareholder Vote Matters — 8-K · 2024-05-09T00:00:00.000Z [neutral] Risk: low
  Eli Lilly and Company (LLY) filed an 8-K on May 9, 2024, to report the submission of matters to a vote of security holders. This filing indicates that the compa
• Eli Lilly Q1 2024 10-Q Filed — 10-Q · 2024-04-30T00:00:00.000Z [neutral] Risk: medium
  Eli Lilly and Company (LLY) filed its 10-Q for the period ending March 31, 2024. The company reported its financial results for the first quarter of 2024, detai
• Eli Lilly Files DEF 14A: Executive Compensation Details — DEF 14A · 2024-03-22T00:00:00.000Z [neutral] Risk: low
  Eli Lilly and Company (LLY) filed its DEF 14A on March 22, 2024, detailing executive compensation and other corporate matters for the fiscal year ending Decembe
• Eli Lilly Details Debt Structure in 2023 10-K Filing — 10-K · 2024-02-21T00:00:00.000Z [neutral] Risk: medium
  Eli Lilly & Co. filed its 10-K on February 21, 2024, for the fiscal year ending December 31, 2023. The filing details various financial instruments, including n
• Vanguard Amends Eli Lilly Stake, Remains Key Passive Investor — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral] Risk: low
  The Vanguard Group, a major investment firm, filed an amendment to its Schedule 13G on February 13, 2024, indicating its ownership of Eli Lilly & Co. common sto
• Eli Lilly Updates Debt Instruments in 8-K Filing — 8-K · 2024-02-09T00:00:00.000Z [neutral] Risk: low
  Eli Lilly and Company filed an 8-K on February 9, 2024, reporting an "Other Event" that occurred on February 7, 2024. This filing primarily updates the company'
• Eli Lilly Files 8-K on Financial Results & Debt Notes — 8-K · 2024-02-06T00:00:00.000Z [neutral]
  Eli Lilly and Company filed an 8-K on February 6, 2024, to report its financial results and condition, specifically mentioning various debt notes with maturity
• BlackRock Amends Eli Lilly Stake, Signals Continued Confidence — SC 13G/A · 2024-01-29T00:00:00.000Z [neutral]
  BlackRock Inc. filed an amended SC 13G/A on January 29, 2024, indicating its ownership of Eli Lilly and Company's common stock as of December 31, 2023. This ame
• Lilly Endowment Amends Eli Lilly Stake, Passive Ownership Confirmed — SC 13G/A · 2024-01-26T00:00:00.000Z [neutral]
  Lilly Endowment Inc. filed an amended SC 13G/A on January 26, 2024, reporting its ownership of Eli Lilly and Company common stock as of December 31, 2023. This